Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Run a search on a company

Kopran Ltd

Pharmaceuticals & Biotechnology | Small Cap

Kopran Ltd Health Insights
Health Score : 6.60Health Score : 6.60

Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.

Latest Report

View All
Quarterly Financial Results Q3 FY 2025-26

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Overview
Ratio
Financial
Kopran Ltd Health Insights
Health Score : 6.60Health Score : 6.60

Kopran Ltd, operating within the Healthcare Services sector, exhibits a mixed financial profile. The company demonstrates very strong solvency and growth, indicating a solid foundation and expansion. Profitability is also a notable strength, reflecting efficient operations and good returns. However, efficiency and financial ratios reveal areas needing attention. Liquidity is average, suggesting moderate short-term financial health. Overall, Kopran Ltd showcases robust growth and profitability, but could benefit from improvements in operational efficiency and financial management to achieve a more balanced and stronger financial standing. While showing good potential, the company's inconsistent financial metrics suggest the need for strategic adjustments to ensure sustained success.

Latest Report

View All
Quarterly Financial Results Q3 FY 2025-26

Latest News

View All

The Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.

Neutral

Overall Valuation Score

Highly Undervalued
Undervalued
Neutral
Overvalued
Highly Overvalued
Neutral

P/E RATIO (TTM)

56.51

Neutral

Industry Median

23.93

Neutral
Neutral

Small Cap Median

23.93

Neutral

P/E RATIO

25.82

P/B RATIO

1.98

Undervalued

Industry Median

2.53

Undervalued
Undervalued

Small Cap Median

2.53

Undervalued

P/S RATIO

1.58

Undervalued

Industry Median

1.35

Undervalued
Undervalued

Small Cap Median

1.35

Undervalued

Others

Overvalued

PEG RATIO

2.08

Overvalued
Overvalued

EV/EBITDA RATIO

12.63

Overvalued

The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹206.27 as on Jun 15, 2026.

Markets Depth NSE

Buy Orders

  1. Bid

    Quantity

    Orders

  2. No buy depth

  3. Total

    0

    0

Sell Orders

  1. Ask

    Quantity

    Orders

  2. No sell depth

  3. Total

    0

    0

BidsOffers
50.00%50.00%

Markets Today NSE

  1. High

    0.00

  2. Low

    0.00

  3. Open

    0.00

  4. Close

    0.00

  5. Prev Close

    0.00

  6. Avg Price

    0.00

  7. Volume

    0

  8. Last Traded Quantity

    0

  9. Last Traded Time

    N/A

Price Movement Indicator

0.00

0.00
Today's Low

0.00
Today's High

Quarterly Report22nd Jan 26

Quarterly Financial Results Q3 FY 2025-26

NEUTRAL SENTIMENT

Growth Ratio Summary
Growth Ratio SummaryGrowth Score : 10.00

The company showcases very strong growth across all metrics. High revenue growth, operating profit growth, EPS growth, asset growth, and net income growth indicate robust expansion and market performance. This suggests effective strategies and strong market positioning. The healthcare industry benefits from consistent growth to meet increasing demand.

ExcellentRevenue Growth RateExcellent
ExcellentOperating Profit Growth RateExcellent
ExcellentEarnings Per Share (EPS) GrowthExcellent
ExcellentAsset Growth RateExcellent
ExcellentNet Income Growth RateExcellent
Growth RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue Growth Rate-2.8515.2711.622.448.1
Operating Profit Growth Rate6.1-40.2342.31-1.35-15.07
Earnings Per Share (EPS) Growth-11.1-55.3787.08-24.41-33.29
Asset Growth Rate39.186.3814.3113.597.58
Net Income Growth Rate-1.61-55.7488.89-23.53-33.33
01.

Revenue Growth Rate

02.

Operating Profit Growth Rate

03.

Earnings Per Share (EPS) Growth

04.

Asset Growth Rate

05.

Net Income Growth Rate

Financial Ratio Summary
Financial Ratio SummaryFinancial Score : 3.20

The company's financial ratios present mixed results. While the dividend per share is reasonable, low adjusted EPS, cash EPS, book value per share, and high capital expenditures suggest areas needing improvement. Enhancing earnings and managing capital expenditures could strengthen financial performance. The healthcare industry requires strong financial management for optimal results.

PoorAdjusted Earnings Per Share (Adjusted EPS)Poor
WeakCash Earnings Per Share (Cash EPS)Weak
PoorBook Value Per SharePoor
AverageDividend Per Share (DPS)Average
PoorCapital Expenditures (CapEx)Poor
Financial RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Adjusted Earnings Per Share (Adjusted EPS)12.715.6210.628.125.42
Cash Earnings Per Share (Cash EPS)158.3313.3311.468.96
Book Value Per Share88.7591.46102.29107.92110.42
Dividend Per Share (DPS)3.042.992.963.040
Capital Expenditures (CapEx)4361575966
01.

Adjusted Earnings Per Share (Adjusted EPS)

02.

Cash Earnings Per Share (Cash EPS)

03.

Book Value Per Share

04.

Dividend Per Share (DPS)

05.

Capital Expenditures (CapEx)

Profitability Ratio Summary
Profitability Ratio SummaryProfitability Score : 9.80

The company exhibits strong profitability. High gross profit margin, ROCE, ROE, ROA, operating margin, and net margin indicate efficient operations and strong returns. This reflects effective management and a competitive market position. The healthcare industry benefits from high profitability to support ongoing operations and growth.

ExcellentGross Profit MarginExcellent
ExcellentReturn on Capital Employed (ROCE)Excellent
ExcellentReturn on Equity (ROE)Excellent
GoodReturn on Assets (ROA)Good
ExcellentOperating MarginExcellent
ExcellentNet MarginExcellent
Profitability RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Gross Profit Margin15.97.089.929.056.61
Return on Capital Employed (ROCE)21814107
Return on Equity (ROE)14.326.1510.397.534.91
Return on Assets (ROA)14.2489.968.656.83
Operating Margin18.29.4412.0311.599.1
Net Margin12.764.98.296.193.82
01.

Gross Profit Margin

02.

Return on Capital Employed (ROCE)

03.

Return on Equity (ROE)

04.

Return on Assets (ROA)

05.

Operating Margin

06.

Net Margin

Efficiency Ratio Summary
Efficiency Ratio SummaryEfficiency Score : 3.00

The company's efficiency ratios indicate potential areas of concern. Turnover ratios are low, suggesting inefficient asset utilization. High days sales in inventory and receivable days point to challenges in managing inventory and collecting payments. Enhancing operational efficiency could improve overall performance. The healthcare industry requires efficient asset management for optimal profitability.

WeakFixed Asset Turnover RatioWeak
WeakInventory Turnover RatioWeak
WeakReceivables Turnover RatioWeak
PoorDays Sales in Inventory RatioPoor
PoorReceivable DaysPoor
PoorCapital Turnover RatioPoor
Efficiency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Fixed Asset Turnover Ratio3.173.343.383.031.85
Inventory Turnover Ratio3.213.644.113.733.82
Receivables Turnover Ratio3.873.83.282.952.85
Days Sales in Inventory Ratio113.71100.2788.8197.8695.55
Receivable Days94.3296.05111.28123.73128.07
Capital Turnover Ratio1.071.211.211.181.25
01.

Fixed Asset Turnover Ratio

02.

Inventory Turnover Ratio

03.

Receivables Turnover Ratio

04.

Days Sales in Inventory Ratio

05.

Receivable Days

06.

Capital Turnover Ratio

Coverage Ratio Summary
Coverage Ratio SummaryCoverage Score : 8.40

The company's coverage ratios are generally strong. A good interest coverage ratio indicates the ability to meet interest obligations, while the equity dividend coverage ratio shows adequate coverage of dividend payments. Maintaining these ratios is crucial for financial stability. The healthcare industry relies on solid coverage ratios for consistent financial performance.

ExcellentInterest Coverage RatioExcellent
AverageEquity Dividend Coverage RatioAverage
Coverage RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Interest Coverage Ratio17.478.566.784.4
Equity Dividend Coverage Ratio4.171.893.572.63
01.

Interest Coverage Ratio

02.

Equity Dividend Coverage Ratio

Solvency Ratio Summary
Solvency Ratio SummarySolvency Score : 10.00

The company exhibits strong solvency. Low debt ratios and high equity ratios indicate a solid financial structure with minimal reliance on debt. This provides a stable base for future growth and financial flexibility. The healthcare industry benefits from strong solvency due to long-term investments and operational stability.

ExcellentDebt RatioExcellent
ExcellentDebt to Equity RatioExcellent
ExcellentEquity RatioExcellent
ExcellentDebt To Asset RatioExcellent
Solvency RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debt Ratio0.040.040.030.030.03
Debt to Equity Ratio0.040.040.030.030.03
Equity Ratio0.960.960.970.970.97
Debt To Asset Ratio0.030.030.020.020.02
01.

Debt Ratio

02.

Debt to Equity Ratio

03.

Equity Ratio

04.

Debt To Asset Ratio

Liquidity Ratio Summary
Liquidity Ratio SummaryLiquidity Score : 5.44

The company's liquidity position shows a mixed performance. While the quick ratio indicates an ability to meet short-term obligations, the low cash ratio and operating cash flow ratio are areas of concern. A higher current ratio provides some buffer, but overall liquidity management could be improved. The healthcare industry often requires maintaining adequate liquidity to handle unforeseen expenses and operational needs.

AverageCurrent RatioAverage
GoodQuick RatioGood
PoorCash RatioPoor
WeakOperating Cash Flow RatioWeak
Liquidity RatiosMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Current Ratio2.562.161.971.691.48
Quick Ratio1.661.481.391.141.02
Cash Ratio0.340.070.060.080.02
Operating Cash Flow Ratio-0.20.180.180.140.18
01.

Current Ratio

02.

Quick Ratio

03.

Cash Ratio

04.

Operating Cash Flow Ratio

Peer Comparison With 19 Companies

Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.

NO Company Name Health Score P/E Ratio Valuation OPM EPS Latest Profit & Loss
1Accent Microcell Ltd7.9624.25Neutral57.0018.2844.00
2Lincoln Pharmaceuticals Ltd7.3113.87Neutral98.0043.8888.00
3NGL Fine Chem Ltd6.9839.09Overvalued73.0067.3948.00
4Medico Remedies Ltd6.6137.70Overvalued17.001.5813.00
5Kilitch Drugs (India) Ltd6.6121.17Neutral37.009.2730.00
6Kopran Ltd6.6025.82Neutral62.006.3026.00
7SMS Lifesciences India Ltd6.5921.78Neutral45.0070.6819.00
8Infinium Pharmachem Ltd6.4226.49Neutral22.006.4314.00
9Sakar Healthcare Ltd5.8158.09Highly Overvalued69.0013.7030.00
10Medicamen Biotech Ltd5.7331.76Neutral20.006.9410.00
11Albert David Ltd5.63-272.76Neutral5.00-2.62-1.00
12BPL Ltd5.46-31.34Neutral-4.82-3.00-8.55
13Zim Laboratories Ltd5.4141.96Neutral30.001.116.00
14Remus Pharmaceuticals Ltd5.3126.36Neutral57.0020.9746.00
15Ind-Swift Laboratories Ltd4.9535.36Neutral45.004.8941.00
16Venus Remedies Ltd4.8323.37Neutral147.0074.30103.00
17Lyka Labs Ltd4.77-24.93Neutral-4.00-9.05-10.00
18Wanbury Ltd4.6528.05Neutral88.0018.9343.00
19Nectar Lifescience Ltd3.83-2.67Neutral-59.00-2.95-293.00
Management Assessment Summary
OrangeBalanced Management

The management of Kopran Ltd. demonstrates a mixed performance. A positive aspect is the consistent promoter holding, indicating a strong alignment with shareholder interests. The company has also achieved sales growth over the past decade. However, there are concerns about the declining profit growth and fluctuating operating profit margins. The increasing debt levels also raise concerns about financial prudence.

Category Metric Value Assessment
PROS Promoter Holding 44.42% Indicates confidence and alignment with shareholders
Sales Growth (10Y) 7% Shows consistent revenue expansion
CONS Compounded Profit Growth (3Y) -14% Indicates declining profitability
Debt/Equity Ratio (Increasing Trend) Increasing Suggests increased financial risk
AverageFinancial Performance & GrowthAverage
AverageCapital Efficiency & ReturnsAverage
WeakFinancial Health & PrudenceWeak
AverageStrategic & Operational IndicatorsAverage
01.

Financial Performance & Growth

02.

Capital Efficiency & Returns

03.

Financial Health & Prudence

04.

Strategic & Operational Indicators

Risk Assessment Summary
OrangeBalanced Risk

Kopran Ltd. presents a moderate risk profile due to volatility in segment performance and increasing regulatory compliance cost trends. Though the company has a stable promoter holding, the increasing Debt levels indicate a potential financial risk.

AverageSegment performance volatilityAverage
AverageRegulatory compliance cost trendsAverage
01.

Segment performance volatility

02.

Regulatory compliance cost trends

0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 2 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 4 Hours Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Day Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Week Timeframe

Overall Score

Strong Bearish

Bearish

Neutral

Bullish

Strong Bullish

Neutral

Market Sentiment

Analysis Driven By 1 Technical Indicators From The 1 Month Timeframe